非酒精性脂肪性肝炎——肝细胞癌发生的前驱病变
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
作者信息
Jiang Chun-Meng, Pu Chun-Wen, Hou Ya-Hui, Chen Zhe, Alanazy Mohammed, Hebbard Lionel
机构信息
Chun-Meng Jiang, Ya-Hui Hou, Department of Digestive System, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, China.
出版信息
World J Gastroenterol. 2014 Nov 28;20(44):16464-73. doi: 10.3748/wjg.v20.i44.16464.
Abstract
Hepatocellular carcinoma (HCC) is increasing in prevalence and is one of the most common cancers in the world. Chief amongst the risks of attaining HCC are hepatitis B and C infection, aflatoxin B1 ingestion, alcoholism and obesity. The later has been shown to promote non alcoholic fatty liver disease, which can lead to the inflammatory form non alcoholic steatohepatitis (NASH). NASH is a complex metabolic disorder that can impact greatly on hepatic function. The mechanisms by which NASH promotes HCC are only beginning to be characterized. Here in this review, we give an overview of the recent novel mechanisms published that have been associated with NASH and subsequent HCC progression. We will focus our discussion on inflammation and gut derived inflammation and how they contribute to NASH driven HCC.
摘要
肝细胞癌（HCC）的患病率正在上升，是世界上最常见的癌症之一。罹患HCC的主要风险包括乙型和丙型肝炎感染、黄曲霉毒素B1摄入、酗酒和肥胖。后者已被证明会促进非酒精性脂肪性肝病，进而可能导致炎症性非酒精性脂肪性肝炎（NASH）。NASH是一种复杂的代谢紊乱疾病，会对肝功能产生重大影响。NASH促进HCC的机制才刚刚开始得到阐明。在这篇综述中，我们概述了最近发表的与NASH及随后的HCC进展相关的新机制。我们将重点讨论炎症和肠道源性炎症，以及它们如何导致NASH驱动的HCC。
相似文献
1
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.非酒精性脂肪性肝炎——肝细胞癌发生的前驱病变
World J Gastroenterol. 2014 Nov 28;20(44):16464-73. doi: 10.3748/wjg.v20.i44.16464.
2
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.肝细胞癌与非酒精性脂肪性肝炎：现状
World J Gastroenterol. 2016 Feb 28;22(8):2494-502. doi: 10.3748/wjg.v22.i8.2494.
3
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
4
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.非酒精性脂肪性肝炎-（NASH-）相关肝细胞癌的分子发病机制。
Can J Gastroenterol Hepatol. 2018 Aug 29;2018:8543763. doi: 10.1155/2018/8543763. eCollection 2018.
5
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
6
Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.用于研究非酒精性脂肪性肝炎衍生的肝细胞癌潜在机制的小鼠模型。
World J Gastroenterol. 2018 May 14;24(18):1989-1994. doi: 10.3748/wjg.v24.i18.1989.
7
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.肝硬化和非肝硬化非酒精性脂肪性肝炎相关肝细胞癌中微生物群多样性和胆汁酸信号的改变
Clin Transl Gastroenterol. 2020 Mar;11(3):e00131. doi: 10.14309/ctg.0000000000000131.
8
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
9
Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.非酒精性脂肪性肝炎和 HCC 在多食的 Western 饮食加速的小鼠中发生。
Cell Mol Gastroenterol Hepatol. 2021;12(3):891-920. doi: 10.1016/j.jcmgh.2021.05.010. Epub 2021 May 29.
10
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.肠道微生物群和氧化应激在非酒精性脂肪性肝病向肝癌进展中的作用：当前和创新的治疗方法。
Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3.
引用本文的文献
1
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.GLP-1 受体激动剂治疗患者肝细胞癌风险的系统评价和荟萃分析。
BMC Endocr Disord. 2024 Nov 18;24(1):246. doi: 10.1186/s12902-024-01775-2.
2
Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.代谢相关脂肪性肝病、脂肪性肝炎、肝纤维化和肝硬化的分子发病机制。
J Cell Mol Med. 2024 Jun;28(12):e18491. doi: 10.1111/jcmm.18491.
3
Unveiling the Impact of ApoF Deficiency on Liver and Lipid Metabolism: Insights from Transcriptome-Wide m6A Methylome Analysis in Mice.揭示载脂蛋白 F 缺乏对肝脏和脂代谢的影响：来自小鼠转录组范围 m6A 甲基组分析的见解。
Genes (Basel). 2024 Mar 9;15(3):347. doi: 10.3390/genes15030347.
4
Triptolide Reduces Neoplastic Progression in Hepatocellular Carcinoma by Downregulating the Lipid Lipase Signaling Pathway.雷公藤甲素通过下调脂酶信号通路减少肝细胞癌的肿瘤进展。
Cancers (Basel). 2024 Jan 27;16(3):550. doi: 10.3390/cancers16030550.
5
The functions and roles of C2H2 zinc finger proteins in hepatocellular carcinoma.C2H2锌指蛋白在肝细胞癌中的功能与作用。
Front Physiol. 2023 Jun 29;14:1129889. doi: 10.3389/fphys.2023.1129889. eCollection 2023.
6
Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights.了解 perilipin 5 在非酒精性脂肪性肝病中的作用及其在肝细胞癌中的作用：新见解综述。
Int J Mol Sci. 2021 May 17;22(10):5284. doi: 10.3390/ijms22105284.
7
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.度拉糖肽单药及与恩格列净联合使用可减轻非糖尿病性NASH小鼠模型中的炎症通路和微生物群失调。
Biomedicines. 2021 Mar 30;9(4):353. doi: 10.3390/biomedicines9040353.
8
9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes.9-磷脂酰高丝氨酸可预防线粒体功能障碍并提高脂肪变性肝细胞的活力。
Int J Mol Sci. 2020 Nov 5;21(21):8279. doi: 10.3390/ijms21218279.
9
A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk.肝癌高危患者筛查实用指南
Mayo Clin Proc Innov Qual Outcomes. 2019 Jul 11;3(3):302-310. doi: 10.1016/j.mayocpiqo.2019.04.005. eCollection 2019 Sep.
10
Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review.非肝硬化肝脏与肝癌预后不良相关：文献综述。
Med Sci Monit. 2019 Sep 3;25:6615-6623. doi: 10.12659/MSM.915722.
本文引用的文献
1
Obesity-associated mechanisms of hepatocarcinogenesis.肥胖相关的肝癌发生机制。
Metabolism. 2014 May;63(5):607-17. doi: 10.1016/j.metabol.2014.01.011. Epub 2014 Feb 5.
2
Multifaceted roles of adiponectin in cancer.脂联素在癌症中的多方面作用。
Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):59-69. doi: 10.1016/j.beem.2013.11.005. Epub 2013 Nov 22.
3
NAFLD, NASH and liver cancer.非酒精性脂肪性肝病、非酒精性脂肪性肝炎和肝癌。
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. doi: 10.1038/nrgastro.2013.183. Epub 2013 Oct 1.
4
Obesity, insulin resistance, NASH and hepatocellular carcinoma.肥胖症、胰岛素抵抗、非酒精性脂肪性肝炎和肝细胞癌。
Semin Cancer Biol. 2013 Dec;23(6 Pt B):483-91. doi: 10.1016/j.semcancer.2013.07.003. Epub 2013 Jul 19.
5
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.非酒精性脂肪性肝炎：发病机制与新型治疗方法。
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212.
6
Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship.肝硬化、胆汁酸和肠道微生物群：揭示复杂的关系。
Gut Microbes. 2013 Sep-Oct;4(5):382-7. doi: 10.4161/gmic.25723. Epub 2013 Jul 12.
7
How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy.细胞因子网络如何引发炎症：迈向基于细胞因子的疾病分类法。
Nat Med. 2013 Jul;19(7):822-4. doi: 10.1038/nm.3260.
8
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.肥胖诱导的肠道微生物代谢物通过衰老分泌组促进肝癌。
Nature. 2013 Jul 4;499(7456):97-101. doi: 10.1038/nature12347. Epub 2013 Jun 26.
9
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.法尼醇 X 受体激动剂奥贝胆酸治疗 2 型糖尿病合并非酒精性脂肪性肝病患者的疗效和安全性。
Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.
10
Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.产丁酸盐益生菌可减少大鼠非酒精性脂肪性肝病的进展：益生菌对肠道-肝脏轴的新见解。
PLoS One. 2013 May 16;8(5):e63388. doi: 10.1371/journal.pone.0063388. Print 2013.
Zotero 插件